Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.81 -3.27%

-$0.20 today

Market cap
$230.39M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.83M

Average 1.29M

Returns on capital

Vanda Pharmaceuticals Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-67.4%

avg -6.9%

ROIC

-43.3%

avg -6.8%

ROA

-45.1%

avg -3.6%

Analysis

ROIC is currently the strongest return metric at -43.3% versus its period average of -6.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Mihael H. Polymeropoulos

Founder, President, Chief Executive Officer & Chairman of The BoardUSD 1.84M66——

Daniel McGuire

Senior Vice President, General Counsel & SecretaryUSD 905.61K———

Joakim Wijkstrom

Senior Vice President & Chief Marketing OfficerUSD 900.03K60333.47K0.55%

Kevin Patrick Moran

Senior Vice President, Chief Financial Officer & TreasurerUSD 882.16K42411.38K0.68%

Gunther Birznieks

Senior Vice President of Business DevelopmentUSD 857.97K57494.20K0.82%

Christos Polymeropoulos

Senior Vice President & Medical Director————

Scott L. Howell

Chief People Officer—51——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$38,093.68

Sells

6

$2.82M

Net Transaction Value

−$2.79M

Net selling

Most Active

Duncan Charles Cliff

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Duncan Charles Cliff

Direct

Buy$22.1K
Nov 4, 26

Duncan Charles Cliff

Direct

Buy$13.2K
Nov 3, 26

Duncan Charles Cliff

Direct

Buy$2.8K
Mar 2, 26

Williams Timothy

Direct

Sell$350.8K
Mar 2, 26

Moran Kevin Patrick

Direct

Sell$350.8K
Mar 2, 26

Wijkstrom Joakim

Direct

Sell$254.6K
Mar 2, 26

Polymeropoulos Mihael Hristos

Direct

Sell$1.3M
Mar 2, 26

Birznieks Gunther

Direct

Sell$350.7K
Feb 23, 26

Honore Tage

Direct

Sell$240.9K

Summary

Insiders reported 3 buys worth $38,093.68 and 6 sells worth $2.82M over the last 12 months. That adds up to net selling of $2.79M. Duncan Charles Cliff was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-5.3%
+17.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -5.3% over three years. Forward estimates point to Revenue at +17.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Vanda Pharmaceuticals Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VNDA's management, answered from reported figures.

Who manages VNDA?

Vanda Pharmaceuticals Inc. (VNDA) lists 7 active executives. The top listed executive is Mihael H. Polymeropoulos, Founder, President, Chief Executive Officer & Chairman of The Board.

Are VNDA insiders buying or selling?

Recent insider activity shows net buying of $6.23M.